Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study

Pentheroudakis, George; Briasoulis, Evangelos; Kalofonos, Haralabos P.; Fountzilas, George; Economopoulos, Theofanis; Samelis, G.F.; Koutras, A.; Karina, M.; Xiros, Nikolaos I.; Samantas, E.; Bamias, Aristotelis; Pavlidis, N.

doi:10.1080/02841860701843043

Cited by 28 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was one consecutive case series study (Gill et al , 1991) and the other 23 studies were single arm clinical trials (Raber et al , 1991; Briasoulis et al , 1998, 2000, 2008; Parnis et al , 2000; Greco et al , 2001, 2002; Guardiola et al , 2001; Macdonald et al , 2002; Balana et al , 2003; Mukai et al , 2003, 2010; Park et al , 2004; Piga et al , 2004; Pouessel et al , 2004; El-Rayes et al , 2005; Pittman et al , 2006; Schneider et al , 2007; Pentheroudakis et al , 2008; Hainsworth et al , 2009; Schuette et al , 2009; Yonemori et al , 2009; Moller et al , 2010). Three trials (Briasoulis et al , 1998, 2000; Pentheroudakis et al , 2008) also involved a small proportion of favourable CUP patients in their studies, and we extracted the data only from the unfavourable subset.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

et al. 2012

View full text Add to dashboard Cite

Background:Although chemotherapeutic regimens containing a taxane or platinum agent have been widely recommended for unfavourable carcinoma of unknown primary (CUP), no evidence exists for the superiority of any administered regimens. To date, the efficacy has been mostly assessed in the limited setting of phase II trials, and few attempts have been made to synthesise all available data for survival outcomes.Methods:Electronic databases were searched from 1980 to 2011. Survival results were combined for each pre-specified category of regimens using a random-effects model, and meta-regression models were used to adjust for heterogeneity in some known prognostic factors.Results:A total of 32 studies were included for meta-analysis. Tendency towards better survival outcome by platinums or taxanes was indicated. After adjustment for important prognostic factors, however, the difference between the platinum-based and non-platinum regimens became no longer significant. Survival benefits by the taxane-based regimens remained significant, with a prolonged median survival time of 1.52 months (P=0.03) and a higher 1-year survival rate of 6.25% (P=0.05), but the benefit did not sustain for 2 years.Conclusion:Although no effective therapies have been established, this meta-analysis helps to fill an important gap of evidence. However, caution should still be taken because of the potential unmeasured confounding.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Three trials (Briasoulis et al , 1998, 2000; Pentheroudakis et al , 2008) also involved a small proportion of favourable CUP patients in their studies, and we extracted the data only from the unfavourable subset.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In 2007 Pentheroudakis G and coll. published a study demonstrating that combination docetaxel carboplatin is a safe and effective palliative option for CUP patients [63]. Also combinatorial triplets with gemcitabine or etoposide, carboplatin, and paclitaxel seem to be tolerable treatment for CUP patients [64,65].…”

Section: Current Therapeutic Approach To Cupsmentioning

confidence: 99%

Cancers of unknown primary origin: current perspectives and future therapeutic strategies

et al. 2012

View full text Add to dashboard Cite

It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and accounts for 3-5% of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology and pathology, which will lead to successful tailored therapeutic options.

show abstract

“…Paclitaxel and docetaxel were used together with cisplatin, carboplatin and gemcitabine. The median survival was reported to be 7-16 months, and the response rates were reported to be between 19.1% and 48.5% [2,21,33,34].…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

et al. 2010

View full text Add to dashboard Cite

The optimal therapy for carcinoma of unknown primary site (CUPS) is still under investigation. In this retrospective trial, we reported the response rates and overall and progression free survival of 23 CUPS patients that were treated with gemcitabine and cisplatin. The mean age of the patients was 54.95 (32-77). Sixteen (69.6%) of them were males and 7(30.4%) females. Totally 109 cycles with a mean of 6 were administered. Thirteen of 23 patients (56.5%) presented with only one metastatic site, and the liver is the most frequent metastatic site (39.1%). Histologic types were adenocarcinoma in 14 patients (60.8%), squamous carcinoma in 1 patient (4.8%), epithelioid cancer in 3 patients (13%) and undifferentiated cancer in 5 patients (21.7%). Three patient achieved a CR (13%), 4 patients achieved a PR (17.4%) and 8 patients had SD (34.8%) with an overall 30.4% response rate. However, 8 patients had progressive disease with a percentage of 34.8%. The median follow-up time was 10 months (3-42 months). The mean and median survival was 12.5 (3-42) months and 10 months (range, 3-42 months) and progression free survival was 5.5 months (range, 0-23 months). Gemcitabine plus cisplatin may be an effective treatment of CUPS. Therefore additional trials are needed especially with new chemotherapeutics.

show abstract

Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study

Cited by 28 publications

References 30 publications

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

Cancers of unknown primary origin: current perspectives and future therapeutic strategies

Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

Contact Info

Product

Resources

About